Takeda Pharmaceutical Co Ltd (TAK) Given $26.75 Average Price Target by Brokerages

Shares of Takeda Pharmaceutical Co Ltd (NYSE:TAK) have earned a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that cover the stock, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy recommendation.

Analysts have set a twelve-month consensus price objective of $26.75 for the company, according to Zacks. Zacks has also assigned Takeda Pharmaceutical an industry rank of 75 out of 256 based on the ratings given to its competitors.

Several equities analysts recently commented on the stock. Zacks Investment Research downgraded shares of Takeda Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Friday, May 17th. ValuEngine cut shares of Takeda Pharmaceutical from a “hold” rating to a “sell” rating in a report on Wednesday, May 15th. Finally, Goldman Sachs Group reaffirmed a “buy” rating on shares of Takeda Pharmaceutical in a research note on Tuesday, March 19th.

Several institutional investors have recently added to or reduced their stakes in TAK. Hudock Capital Group LLC bought a new position in shares of Takeda Pharmaceutical in the first quarter valued at $26,000. Shine Investment Advisory Services Inc. purchased a new position in Takeda Pharmaceutical in the first quarter valued at about $28,000. Contravisory Investment Management Inc. purchased a new position in Takeda Pharmaceutical in the first quarter valued at about $28,000. Assetmark Inc. purchased a new position in Takeda Pharmaceutical in the first quarter valued at about $28,000. Finally, Cresset Asset Management LLC purchased a new position in Takeda Pharmaceutical in the first quarter valued at about $33,000. 11.45% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NYSE:TAK traded up $0.48 on Friday, reaching $17.11. 1,068,350 shares of the company’s stock were exchanged, compared to its average volume of 3,517,479. Takeda Pharmaceutical has a twelve month low of $15.50 and a twelve month high of $21.95. The firm has a market cap of $26.29 billion, a PE ratio of 33.55 and a beta of 0.69. The company has a quick ratio of 0.82, a current ratio of 1.22 and a debt-to-equity ratio of 0.92.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines.

Read More: Marijuana Stocks

Get a free copy of the Zacks research report on Takeda Pharmaceutical (TAK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.